Adavivint free base · Synonyms: SM04690 | Lorecivivint

Adavivint is a potent and selective inhibitor of canonical Wnt signaling.

For research use only. Not for human or veterinary use.

Target Wnt

Research area Inflammation/Immunology Cancer

Purity >98% Stock Inquire

Data Sheet SDS COA

Adavivint structure

CAS No.: 1467093-03-3

Download structure (.mol)

Pack sizes & pricing

Size	Price	SKU	Stock
100 mg	USD 380.00	BP-01894-100mg	In stock	Get quote
250 mg	USD 580.00	BP-01894-250mg	In stock	Get quote
500 mg	USD 880.00	BP-01894-500mg	In stock	Get quote
1 g	USD 1,380.00	BP-01894-1g	In stock	Get quote
2 g	Inquire	BP-01894-2g	Inquire	Inquire
5 g	Inquire	BP-01894-5g	Inquire	Inquire

Custom Size Bulk Inquiry

Description

Adavivint (SM04690; Lorecivivint) is a potent and selective inhibitor of canonical Wnt signaling, with an EC50 of 19.5 nM via a high-throughput TCF/LEF-reporter assay in SW480 colon cancer cells.

Biological activity

In Vitro Adavivint (SM04690) is a potent and selective inhibitor of Wnt signaling, with an EC50 of 19.5 nM via a high-throughput TCF/LEF-reporter assay in SW480 colon cancer cells, and shows no effect on SV40 luciferase reporter. Adavivint enhances aggregation of human mesenchymal stem cells (hMSCs) with an EC50 of 10 nM. Adavivint (30 nM) protects chondrocytes from catabolic breakdown in vitro. In Vivo Adavivint (0.3 μg) enhances cartilage repair and protection in the rat acute cruciate ligament tear and partial medial meniscectomy osteoarthritis (ACLT + pMMx OA) model.

Identifiers

SMILES: CC(C)CC(=O)NC1=CC(=CN=C1)C1=CC2=C(NN=C2C2=NC3=C(N2)C(=CN=C3)C2=CC=CC(F)=C2)C=C1
InChIKey: AQDWDWAYVBQMAM-UHFFFAOYSA-N

Specifications

MW (average): 505.5456
Formula: C₂₉H₂₄FN₇O
CAS No.: 1467093-03-3
Physical state: Solid
Color: Light yellow to gray
Shipping: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage: Powder -20℃ 2 years; In solvent -20℃ 1 month;

Solubility

Soluble in DMSO

Documents

References

[1]. Deshmukh V, et al. A small-molecule inhibitor of the Wnt pathway (SM04690) as a potential disease modifying agent for the treatment of osteoarthritis of the knee. Osteoarthritis Cartilage. 2018 Jan;26(1):18-27. doi: 10.1016/j.joca.2017.08.015. Epub 2017 Sep 6. PubMed PMID: 28888902.

[2]. Yazici Y, et al. A novel Wnt pathway inhibitor, SM04690, for the treatment of moderate to severe osteoarthritis of the knee: results of a 24-week, randomized, controlled, phase 1 study. Osteoarthritis Cartilage. 2017 Oct;25(10):1598-1606. doi:10.1016/j.joca.2017.07.006. Epub 2017 Jul 13. PubMed PMID: 28711582.

Same target

Search Wnt

Same research area

Search Inflammation/Immunology